Principal Investigators:
José Szapocznik, PhD
Lisa Metsch, PhD [email]
Miller School of Medicine
University of Miami
1425 NW 10th Ave, Room 309
Miami, FL 33136

Find Node Publications
Node Facebook page
Node web site
NIDA web site

The Florida Node was renamed the Florida Node Alliance in 2010 and represents a collaboration of scientists and practitioners from programs involved in drug and alcohol treatment and research from a variety of treatment settings and patient populations, representing diverse geographic and regional representations that allow great variety and generalizability in the types of studies conducted.  The Florida Node Alliance includes the Center for Family Studies in the Department of Epidemiology and Public Health at the Miller School of Medicine, University of Miami, as well as community treatment programs (CTPs) in Florida, Colorado, North Carolina, Georgia, Massachusetts, Puerto Rico, and the Virgin Islands. These CTPs serve urban and semi-rural areas, and treat ethnically and racially diverse populations. The varied treatment settings include: 1) traditional community-based drug treatment programs, 2) primary care physician network, primary care centers and emergency departments, 3) STD clinics/public health clinics, 4) HIV outpatient and inpatient centers, and 5) Veterans Affairs medical centers.The node has considerable expertise in: 1) adolescent and  family treatment, 2) treatment for HIV/AIDS populations, 3) aggressive engagement of drug abusers into treatment,  4) psychopharmacological treatment and comobribd conditions, 5) Health Economics, 6) E technology.  The node has a special interest and expertise with Spanish speaking populations both in the US and abroad.


CTN-0001 Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification
CTN-0006 Motivational Incentives for Enchanced Drug Abuse Recovery: Drug Free Clinics
CTN-0008 Assessment of the National Drug Abuse Clinical Trials Network: A Baseline for Investigating Diffusion of Innovation
CTN-0012 Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infections, and Sexually Transmitted Infections in Substance Abuse Treatment Programs
CTN-0014 Brief Strategic Family Therapy for Adolescent Drug Abusers
CTN-0014-A-1 Mediators and Moderators of Brief Strategic Family Therapy (BSFT) for Adolescent Drug Use
CTN-0015 Women's Treatment for Trauma and Substance Use Disorders
CTN-0021 Motivational Enhancement Treatment to Improve Treatment Engagement and Outcome for Spanish-Speaking Individuals Seeking Treatment for Substance Abuse
CTN-0028 Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents (with Substance Use Disorder)
CTN-0031 Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement
CTN-0032 HIV Rapid Testing and Counseling
CTN-0032-A-1 Economic Analysis of HIV Rapid Testing in Drug Abuse Treatment Programs
CTN-0037 Stimulant Reduction Intervention Using Dosed Exercise (STRIDE)
CTN-0037-A-1 Site Influences on Treatment Effects - Exercise as a Treatment for Substance Use Disorders
CTN-0044 Web-Delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders
CTN-0045-Ot Rates of HIV Testing and Barriers to Testing in African Americans Receiving Substance Abuse Treatment
CTN-0046 Smoking Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking Cessation and Stimulant Treatment on Stimulant Dependence
CTN-0047 Screening, Motivational Assessment, Referral and Treatment in Emergency Departments (SMART-ED): Evaluation of Screening, Brief Intervention, Referral to Treatment (SBIRT) and Booster Session for Drug Use Patients Presenting for Treatment in the Emergency Department
CTN-0049 Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users (Project HOPE)
CTN-0051 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)
CTN-0051-A-1 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT) Genetics Study
CTN-0051-A-2 Treatment-As-Usual Opioid Use Outcomes Following Discharge from Detoxification and Short-Term Residential Programs Affiliated with CTN-0051
CTN-0052 A Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults with Cocaine Dependence (BRAC)
CTN-0064 Linkage to Hepatitis C Virus (HCV) Care among HIV/HCV Co-infected Substance Users

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 5/2016 -- http://ctndisseminationlibrary.org/nodes/fnanode.htm